Shots:

• The US FDA has granted expanded approval to the Enstilar foam- 0.005%/0.064% supported by the Enstilar Pediatric study evaluating it in adolescents with plaque psoriasis aged ≥12yrs. The FDA has extended its market exclusivity by an additional six mos. to Dec 10- 2031
• Additionally- the FDA has approved Taclonex topical suspension for scalp and body plaque psoriasis in patients aged ≥12yrs.
• Enstilar Foam is a combination of calcipotriene- a vitamin D analog- and betamethasone dipropionate- a corticosteroid while Taclonex is a combination of betamethasone and calcipotriene in which betamethasone prevents the release of the substance causing inflammation in the body

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Pharmastar